MilliporeSigma
  • Home
  • Search Results
  • Methyl salicylate lactoside inhibits inflammatory response of fibroblast-like synoviocytes and joint destruction in collagen-induced arthritis in mice.

Methyl salicylate lactoside inhibits inflammatory response of fibroblast-like synoviocytes and joint destruction in collagen-induced arthritis in mice.

British journal of pharmacology (2014-04-10)
Wenyu Xin, Chao Huang, Xue Zhang, Sheng Xin, Yiming Zhou, Xiaowei Ma, Dan Zhang, Yongjie Li, Sibai Zhou, Dongming Zhang, Tiantai Zhang, Guanhua Du
ABSTRACT

Methyl salicylate 2-O-β-d-lactoside (MSL), whose chemical structure is similar to that of salicylic acid, is a natural product derivative isolated from a traditional Chinese herb. The aim of this study was to investigate the therapeutic effect of MSL in mice with collagen-induced arthritis (CIA) and explore its underlying mechanism. The anti-arthritic effects of MSL were evaluated on human rheumatoid fibroblast-like synoviocytes (FLS) in vitro and CIA in mice in vivo by obtaining clinical scores, measuring hind paw thickness and inflammatory cytokine levels, radiographic evaluations and histopathological assessments. Treatment with MSL after the onset of arthritis significantly prevented the progression and development of rheumatoid arthritis (RA) in CIA mice without megascopic gastric mucosa damage. In addition, MSL inhibited the production of pro-inflammatory mediators, the phosphorylation and translocation of NF-κB, and cell proliferation induced by TNF-α in FLS. MSL non-selectively inhibited the activity of COX in vitro, but was a more potent inhibitor of COX-2 than COX-1. MSL also inhibited the phosphorylation of inhibitor of NF-κB kinase, IκBα and p65, thus blocking the nuclear translocation of NF-κB in TNF-α-stimulated FLS. MSL exerts therapeutic effects on CIA mice, suppressing the inflammatory response and joint destruction by non-selectively inhibiting the activity of COX and suppressing activation of the NF-κB signalling pathway, but without damaging the gastric mucosa. Therefore, MSL has great potential to be developed into a novel therapeutic agent for the treatment of RA.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Cyclooxygenase 2 human, ≥70% (SDS-PAGE), recombinant, expressed in insect cells, aqueous solution, ≥8000 units/mg protein
Sigma-Aldrich
Anti-RELA (Ab-468) antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Phenylmethanesulfonyl fluoride, ≥98.5% (GC)
Sigma-Aldrich
Phenylmethanesulfonyl fluoride, ≥99.0% (T)
Sigma-Aldrich
HEPES buffer solution, 1 M in H2O
Sigma-Aldrich
HEPES, BioUltra, for molecular biology, ≥99.5% (T)
SAFC
HEPES
Sigma-Aldrich
Anti-RELA (Ab-254) antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-RELA (Ab-276) antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-RELA (Ab-435) antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-RELA (Ab-311) antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-RELA (Ab-529) antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-RELA (Ab-536) antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-RELA (Ab-505) antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
HEPES, BioXtra, suitable for mouse embryo cell culture, ≥99.5% (titration)
Sigma-Aldrich
HEPES, ≥99.5% (titration)
Sigma-Aldrich
HEPES, BioPerformance Certified, ≥99.5% (titration), suitable for cell culture
Sigma-Aldrich
HEPES, BioXtra, pH 5.0-6.5 (1 M in H2O), ≥99.5% (titration)
Supelco
HEPES, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
HEPES, anhydrous, free-flowing, Redi-Dri, ≥99.5%
SAFC
HEPES